Literature DB >> 25908646

Melatonin: Physiological effects in humans.

B Claustrat1, J Leston2.   

Abstract

Melatonin is a methoxyindole synthesized and secreted principally by the pineal gland at night under normal light/dark conditions. The endogenous rhythm of secretion is generated by the suprachiasmatic nuclei and entrained to the light/dark cycle. Light is able to either suppress or synchronize melatonin production according to the light schedule. The nycthohemeral rhythm of this hormone can be evaluated by repeated measurement of plasma or saliva melatonin or urine sulfatoxymelatonin, the main hepatic metabolite. The primary physiological function of melatonin, whose secretion adjusts to night length, is to convey information concerning the daily cycle of light and darkness to body structures. This information is used for the organisation of functions, which respond to changes in the photoperiod such as the seasonal rhythms. Seasonal rhythmicity of physiological functions in humans related to possible alteration of the melatonin message remains, however, of limited evidence in temperate areas under field conditions. Also, the daily melatonin secretion, which is a very robust biochemical signal of night, can be used for the organisation of circadian rhythms. Although functions of this hormone in humans are mainly based on correlations between clinical observations and melatonin secretion, there is some evidence that melatonin stabilises and strengthens coupling of circadian rhythms, especially of core temperature and sleep-wake rhythms. The circadian organisation of other physiological functions depend also on the melatonin signal, for instance immune, antioxidant defences, haemostasis and glucose regulation. The difference between physiological and pharmacological effects of melatonin is not always clear but is based upon consideration of dose and not of duration of the hormone message. It is admitted that a "physiological" dose provides plasma melatonin levels in the same order of magnitude as a nocturnal peak. Since the regulating system of melatonin secretion is complex, following central and autonomic pathways, there are many pathophysiological situations where melatonin secretion can be disturbed. The resulting alteration could increase the predisposition to disease, add to the severity of symptoms or modify the course and outcome of the disorder. Since melatonin receptors display a very wide distribution in the body, putative therapeutic indications of this compound are multiple. Great advances in this field could be achieved by developing multicentre trials in a large series of patients, in order to establish efficacy of melatonin and absence of long-term toxicity.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Circadian rhythms; Glande pinéale; Humain; Human; Melatonin; Mélatonine; Pathophysiology; Physiologie; Physiology; Rythmes circadiens

Mesh:

Substances:

Year:  2015        PMID: 25908646     DOI: 10.1016/j.neuchi.2015.03.002

Source DB:  PubMed          Journal:  Neurochirurgie        ISSN: 0028-3770            Impact factor:   1.553


  96 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Effect of long-term treatment with melatonin on vascular markers of oxidative stress/inflammation and on the anticontractile activity of perivascular fat in aging mice.

Authors:  Claudia Agabiti-Rosei; Gaia Favero; Carolina De Ciuceis; Claudia Rossini; Enzo Porteri; Luigi Fabrizio Rodella; Lorenzo Franceschetti; Anna Maria Sarkar; Enrico Agabiti-Rosei; Damiano Rizzoni; Rita Rezzani
Journal:  Hypertens Res       Date:  2016-08-18       Impact factor: 3.872

Review 3.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 4.  The Safety of Melatonin in Humans.

Authors:  Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg; Russel J Reiter
Journal:  Clin Drug Investig       Date:  2016-03       Impact factor: 2.859

Review 5.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 6.  Melatonin and its mechanism of action in the female reproductive system and related malignancies.

Authors:  Maryam Ezzati; Kobra Velaei; Raziyeh Kheirjou
Journal:  Mol Cell Biochem       Date:  2021-04-17       Impact factor: 3.396

7.  Melatonin promotes Cashmere goat (Capra hircus) secondary hair follicle growth: a view from integrated analysis of long non-coding and coding RNAs.

Authors:  Wei Ge; Shan-He Wang; Bing Sun; Yue-Lang Zhang; Wei Shen; Hasan Khatib; Xin Wang
Journal:  Cell Cycle       Date:  2018-07-17       Impact factor: 4.534

8.  Oral Administration of Melatonin or Succinyl Melatonin Niosome Gel Benefits 5-FU-Induced Small Intestinal Mucositis Treatment in Mice.

Authors:  Prangtip Uthaiwat; Aroonsri Priprem; Sirinart Chio-Srichan; Chatri Settasatian; Yao-Chang Lee; Pramote Mahakunakorn; Patcharee Boonsiri; Chanvit Leelayuwat; Patcharaporn Tippayawat; Ploenthip Puthongking; Jureerut Daduang
Journal:  AAPS PharmSciTech       Date:  2021-07-01       Impact factor: 3.246

Review 9.  The importance of 24-h metabolism in obesity-related metabolic disorders: opportunities for timed interventions.

Authors:  Charlotte Andriessen; Patrick Schrauwen; Joris Hoeks
Journal:  Int J Obes (Lond)       Date:  2020-11-24       Impact factor: 5.095

10.  A Case Control Study on Serum Levels of Potential Biomarkers in Male Breast Cancer Patients.

Authors:  Kamal Eldin Ahmed Abdelsalam; Mohammed Asad; Monjid Ahmed Ibrahim Ahmed; Syed Mohammed Basheeruddin Asdaq; Yahya Mohzari; Ahmed Alrashed; NajwaJilan Alghamdi; Kholoud Nasser Alrami; Wael Ahmed Alharbi
Journal:  Int J Environ Res Public Health       Date:  2021-05-01       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.